Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | USP2 | O75604 | 9/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18701847 | 0.82 | EPHX2 (0.40) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL29088302 | 0.82 | TSHR (0.60) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL22794820 | 0.82 | PIK3CD (0.62) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL23696325 | 0.81 | CYP2D6 (0.58) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL24926106 | 0.80 | PIK3CD (0.63) | CYP2D6TSHRCYP2C9CYP3A4MEN1 | |
| SCHEMBL25928035 | 0.79 | CYP2D6 (0.57) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL25904088 | 0.78 | EPHX2 (0.38) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL23945973 | 0.77 | CYP2D6 (0.54) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL22848880 | 0.77 | CYP2D6 (0.54) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL21787313 | 0.77 | CYP2D6 (0.54) | CYP2D6TSHRUSP2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.